В. А. Горбунова

13.9k citations

61 papers · 7.2k indexed · 4 hit papers · h-index 24

Pulmonary and Respiratory Medicine top 0.2%
- Lung Cancer Treatments and Mutations 23
- Gastric Cancer Management and Outcomes 20
- Lung Cancer Diagnosis and Treatment 7
- Brain Metastases and Treatment 5
Oncology top 0.5%
- Colorectal Cancer Treatments and Studies 20
- Lung Cancer Research Studies 15
- Cancer Treatment and Pharmacology 7
Cancer Research top 1%
Gastroenterology top 1%
- Gastrointestinal Tumor Research and Treatment 6
Molecular Biology top 5%

Co-authors: Jaafar Bennouna Tony Mok Lecia V. Sequist Wu‐Chou Su James Chih‐Hsin Yang Michael Boyer Mehdi Shahidi Dan Massey
Cited by: Pulmonary and Respiratory Medicine Oncology Cancer Research
Partner nations: Russia United States Germany

In The Last Decade

В. А. Горбунова

53 papers receiving 7.0k citations

Hit Papers

align trajectories log scale

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

2013 Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations
2013 Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial
2010 Multicenter Phase III Comparison of Cisplatin/S-1 With Cisplatin/Infusional Fluorouracil in Advanced Gastric or Gastroesophageal Adenocarcinoma Study: The FLAGS Trial
2007 Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

Peers

Countries citing papers authored by В. А. Горбунова

Since Specialization

Citations

This map shows the geographic impact of В. А. Горбунова's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by В. А. Горбунова with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites В. А. Горбунова more than expected).

Fields of papers citing papers by В. А. Горбунова

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by В. А. Горбунова. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by В. А. Горбунова. The network helps show where В. А. Горбунова may publish in the future.

Co-authorship network

The 25 scholars most cited alongside В. А. Горбунова, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with В. А. Горбунова Line = papers co-authored together В. А. Горбунова links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	44P Reintroduction of platinum-based chemotherapy ± mitotane for advanced adrenocortical cancer: Single-center retrospective trial Yaroslav Zhulikov,Е. I. Kovalenko,Е. V. Artamonova,V. Bohian,Е. В. Евдокимова,В. А. Горбунова,Olga Martynova,V. Delektorskaya,И. С. Стилиди	2025	0
2	Targeted therapy in the treatment of HER-2 positive breast cancer with brain metastases Д. Р. Насхлеташвили,K. E. Roshchina,В. А. Горбунова,T. G. Gasparyan,Bychkov Mb,A. Кh. Bekyashev,В. Б. Карахан,Е. А. Москвина,В. А. Алешин,Д. М. Белов,A. A. Мitrоfаnоv,Е. В. Прозоренко,A. A. Pogosova	2020	0
3	TAGS: A phase III, randomised, double-blind study of trifluridine/tipiracil (TAS-102) versus placebo in patients with refractory metastatic gastric cancer Hendrik‐Tobias Arkenau,Josep Tabernero,Kohei Shitara,Mikhail Dvorkin,Was Mansoor,Aliaksandr Prokharau,María Alsina,Michele Ghidini,C. Faustino,В. А. Горбунова,Э. А. Жаврид,Kazuhiro Nishikawa,A. Hosokawa,Doina Ganea,Şuayib Yalçın,Giordano Beretta,R.E. Winkler,Lukas Makris,Toshihiko Doi,D.H. Ilson	2018	1
4	A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)–only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer Rebecca Kristeleit,Ірина Давиденко,Vadim Shirinkin,Fatima El-Khouly,Igor Bondarenko,Michael J. Goodheart,В. А. Горбунова,C A Penning,Jack Shi,Xiangdong Liu,Robert Newton,Yufan Zhao,Janet Maleski,Lance Leopold,Russell J. Schilder	2017	78
5	A phase III trial comparing oral S-1/cisplatin and intravenous 5-fluorouracil/cisplatin in patients with untreated diffuse gastric cancer Jaffer A. Ajani,Mikhail Abramov,Igor Bondarenko,Y. Shparyk,В. А. Горбунова,A. Hontsa,N. M. Otchenash,María Alsina,Sergey Lazarev,Jaime Feliú,Anneli Elme,V. Esko,Kathia Cristina Abdalla,Udit Verma,Fabio Benedetti,Takekazu Aoyama,Hirokazu Mizuguchi,Lukas Makris,Gerardo Rosati	2017	37
6	Randomized, Placebo-Controlled, Phase II Study of Veliparib in Combination with Carboplatin and Paclitaxel for Advanced/Metastatic Non–Small Cell Lung Cancer Suresh S. Ramalingam,Normand Blais,Julien Mazières,Martin Reck,C. Michael Jones,Erzsébet Juhász,László Urbán,С. В. Орлов,Fabrice Barlési,Ebenezer A. Kio,Ulrich Keiholz,Qin Qin,Jiang Qian,Caroline Nickner,Juliann Dziubinski,Hao Xiong,Peter Ansell,Mark D. McKee,Vincent L. Giranda,В. А. Горбунова	2016	65
7	THE COMPARISON OF THE THERAPEUTIC EQUIVALENCE OF OXALIPLATINRONC® (BRANCH “NAUKOPROFI” OF N.N. BLOKHIN RCRC) AND ELOXATIN® (AVENTIS PHARMA LTD, GREAT BRITAIN) IN MFOLFOX6 COMBINATION AS A FIRST LINE OF CHEMOTHERAPY IN PATIENTS WITH METASTATIC COLORECTAL CANCER A. А. Kolomeytseva,S. V. Kopachevskaia,Н. Ф. Орел,В. А. Горбунова,T. Y. Eskina,M. Yu. Fedyanin,L. V. Manzyuk,A. V. Snegovoy,L. S. Scriabina,Guzel Mukhametshina,А. С. Одинцова,E. V. Trusilova,F. H. Mukhametgaleeva,O. V. Sehina,Yu. V. Vakhabova,Н. В. Доброва,E. V. Chtrnoglazova	2016	1
8	DRUG THERAPY OF BREAST CANCER PATIENTS WITH METASTATIC BRAIN LESIONS. Д. Р. Насхлеташвили,В. А. Горбунова,Е. А. Москвина,A. Кh. Bekyashev,V. B. Karakhan,З. П. Михина,С. В. Медведев	2015	0
9	Pharmacoeconomic analysis of Giotrif® (afatinib) as first-line treatment of metastatic non-small cell lung cancer with Del19 mutation of epidermal growth factor receptor (EGFR) gene В. А. Горбунова,С. В. Орлов,S. К. Zyryanov,D. Yu. Belousov	2015	1
10	STUDY DATA OF KRAS- AND RAS-UNMUTATED (WILD) TYPE OF COLORECTAL CANCER В. А. Горбунова	2015	1
11	A Correlative Biomarker Analysis of the Combination of Bevacizumab and Carboplatin-Based Chemotherapy for Advanced Nonsquamous Non–Small-Cell Lung Cancer: Results of the Phase II Randomized ABIGAIL Study (BO21015) Tony Mok,В. А. Горбунова,Erzsébet Juhász,B. Szima,Olga Burdaeva,С. В. Орлов,Chong‐Jen Yu,Venice Archer,Magalie Hilton,Paul Delmar,Céline Pallaud,Martin Reck	2014	39
12	Maintenance bevacizumab–pemetrexed after first-line cisplatin–pemetrexed–bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial Fabrice Barlési,Arnaud Scherpereel,В. А. Горбунова,R. Gervais,Anders Vikström,C. Chouaïd,Antonio Chella,J.H. Kim,Myung‐Ju Ahn,Martin Reck,Antonio Pazzola,H. T. Kim,Joachim G.J.V. Aerts,Claire Morando,Anderson Loundou,Harry J.M. Groen,Achim Rittmeyer	2014	129
13	Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutationsbreakdown → Lecia V. Sequist,James Chih‐Hsin Yang,Nobuyuki Yamamoto,Kenneth J. O’Byrne,Vera Hirsh,Tony Mok,Sarayut Lucien Geater,С. В. Орлов,Chun‐Ming Tsai,Michael Boyer,Wu‐Chou Su,Jaafar Bennouna,Terufumi Kato,В. А. Горбунова,Ki Hyeong Lee,Riyaz Shah,Dan Massey,Victoria Zazulina,Mehdi Shahidi,Martin Schüler	2013	2461
14	Health-Related Quality of Life in Patients with Advanced Nonsquamous Non–Small-Cell Lung Cancer Receiving Bevacizumab or Bevacizumab-Plus-Pemetrexed Maintenance Therapy in AVAPERL (MO22089) Achim Rittmeyer,В. А. Горбунова,Anders Vikström,Arnaud Scherpereel,Joo-Hang Kim,Myung‐Ju Ahn,Antonio Chella,C. Chouaïd,Alicyn Campbell,Fabrice Barlési	2013	23
15	Modern treatment in patients of malignant plevral effusions resistent sistem therapy Bychkov Mb,К. С. Титов,В. А. Горбунова,Dmitry Filonenko,Lev Demidov,Mikhail Kiselevskiy,E. M Trechalina	2013	0
16	Multicenter Phase III Comparison of Cisplatin/S-1 With Cisplatin/Infusional Fluorouracil in Advanced Gastric or Gastroesophageal Adenocarcinoma Study: The FLAGS Trialbreakdown → Jaffer A. Ajani,W. Rodriguez,G. Bodoky,Vladimir Moiseyenko,Mikhail Lichinitser,В. А. Горбунова,Ihor Vynnychenko,August Garin,István Láng,S. Falcon	2010	425
17	Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trialbreakdown → Bernard Escudier,A Płużańska,P. Koralewski,Alain Ravaud,Sergio Bracarda,Cezary Szczylik,Christine Chevreau,M. Filipek,Bohuslav Melichar,Emilio Bajetta,В. А. Горбунова,Jacques‐Olivier Bay,I. Bodrogi,Agnieszka Jagiełło-Gruszfeld,N. Moore	2007	1722
18	B1-06: Multicenter, randomized study of Docetaxel versus Docetaxel plus Oblimersen in patients previously treated for non-small cell lung cancer (NSCLC) Roy S. Herbst,Rafat Ansari,В. А. Горбунова,Georgy M. Manikhas,Mansoor N. Saleh,Thomas E. Boyd,Christopher G. Azzoli,Francisco Robert,Loretta M. Itri,Robert Chapman	2007	2
19	Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study Carmelo Pozzo,C. Barone,J. Szántó,Éva Pádi,Christian Peschel,Johannes Bükki,В. А. Горбунова,Vahur Valvere,J. Załuski,M. Biakhov,Emmanuel Zuber,Christian Jacques,R. Bugat	2004	126
20	Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases Jean‐Jacques Body,Ingo Diel,М. Р. Личиницер,E.D. Kreuser,W. Dornoff,В. А. Горбунова,M. Budde,B. Bergström	2003	296

About В. А. Горбунова

В. А. Горбунова is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Gastroenterology, having authored 61 papers that have together received 7.2k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (23 papers), Colorectal Cancer Treatments and Studies (20 papers), Gastric Cancer Management and Outcomes (20 papers), Lung Cancer Research Studies (15 papers), Cancer Treatment and Pharmacology (7 papers), Lung Cancer Diagnosis and Treatment (7 papers), Gastrointestinal Tumor Research and Treatment (6 papers) and Brain Metastases and Treatment (5 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (5.5k citations), Oncology (4.5k citations) and Cancer Research (1.4k citations). В. А. Горбунова has collaborated with scholars based in Russia, United States and Germany. Frequent co-authors include Jaafar Bennouna, Tony Mok, Lecia V. Sequist, Wu‐Chou Su, James Chih‐Hsin Yang, Michael Boyer, Mehdi Shahidi, Dan Massey, Ki Hyeong Lee and Vera Hirsh.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact